Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial

Eur Respir J. 2014 Jan;43(1):295-8. doi: 10.1183/09031936.00140613. Epub 2013 Oct 17.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin / therapeutic use
  • Disease Progression
  • Humans
  • Proportional Hazards Models
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / metabolism*
  • Receptors, Tumor Necrosis Factor, Type II / metabolism*

Substances

  • Anti-Bacterial Agents
  • Receptors, Tumor Necrosis Factor, Type II
  • TNFRSF1B protein, human
  • Azithromycin